

23rd June, 2021

BSE Limited
1st Floor, New Trading Ring,
Rotunda Building, P.J. Towers,
Dalal Street, Fort,
Mumbai - 400 001
BSE scrip code: 500302

National Stock Exchange of India Limited
Exchange Plaza, 5th floor,
Plot No. C/1, G-Block,
Bandra-Kurla Complex, Bandra (E),
Mumbai – 400 051
NSE symbol: PEL

Sub: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and Securities and Exchange Board of India's circular no. CIR/CFD/CMD/4/2015 dated September 9, 2015

Dear Sir/ Madam,

We had, vide our letter dated 31st March, 2021, made a disclosure regarding the acquisition of 100% stake in Hemmo Pharmaceuticals Private Limited ('Hemmo'), for an aggregate cash consideration of Rs. 775 crores and earn-outs linked to achievement of milestones, by Piramal Pharma Limited ('PPL'), subsidiary of the Company ('Transaction').

We wish to inform you that PPL has completed the acquisition of Hemmo on 22nd June, 2021 and the Transaction is now closed.

This is for your information and records.

Thanking you,

Yours faithfully,
For Piramal Enterprises Limited

Bipin Singh
Company Secretary

Piramal Enterprises Limited

CIN : L24110MH1947PLC005719

Registered Office: Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai 400 070 India
Secretarial Dept : Ground Floor, B Block, Agastya Corporate Park, Opp. Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai, Maharashtra 400070, India
T +91 22 3802 3084/3083/3103 F +91 22 3802 3084

piramal.com